- Home
- GAME vs CYTH Comparison
GAME vs CYTH Comparison
Compare GAME & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- CYTH
- Stock Information
- Founded
- GAME 2011
- CYTH 1990
- Country
- GAME United States
- CYTH United States
- Employees
- GAME N/A
- CYTH N/A
- Industry
- GAME
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- CYTH Health Care
- Exchange
- GAME Nasdaq
- CYTH Nasdaq
- Market Cap
- GAME 23.2M
- CYTH 22.0M
- IPO Year
- GAME 2009
- CYTH N/A
- Fundamental
- Price
- GAME $0.80
- CYTH $0.81
- Analyst Decision
- GAME Strong Buy
- CYTH Buy
- Analyst Count
- GAME 2
- CYTH 3
- Target Price
- GAME $4.00
- CYTH $0.95
- AVG Volume (30 Days)
- GAME 361.0K
- CYTH 32.7K
- Earning Date
- GAME 11-14-2024
- CYTH 11-12-2024
- Dividend Yield
- GAME N/A
- CYTH N/A
- EPS Growth
- GAME N/A
- CYTH N/A
- EPS
- GAME N/A
- CYTH N/A
- Revenue
- GAME $84,160,866.00
- CYTH $1,132,430.00
- Revenue This Year
- GAME $113.45
- CYTH N/A
- Revenue Next Year
- GAME $19.68
- CYTH $24.49
- P/E Ratio
- GAME N/A
- CYTH N/A
- Revenue Growth
- GAME 175.59
- CYTH 24.65
- 52 Week Low
- GAME $0.65
- CYTH $0.59
- 52 Week High
- GAME $2.30
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- GAME 49.55
- CYTH 57.39
- Support Level
- GAME $0.65
- CYTH $0.75
- Resistance Level
- GAME $1.15
- CYTH $0.80
- Average True Range (ATR)
- GAME 0.08
- CYTH 0.06
- MACD
- GAME 0.03
- CYTH 0.01
- Stochastic Oscillator
- GAME 29.80
- CYTH 100.00
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is a vertically integrated, digital media, entertainment and technology company that connects brands with gaming and youth culture audiences. The company's end-to-end platform includes Gaming Community Network (a "GCN"), a digital media company focused on gaming and esports audiences, Swingman LLC dba as Zoned, a gaming and lifestyle marketing agency, and Code Red Esports Ltd. The company's geographical segment includes the United Kingdom, the USA, and Spain. The company generates the majority of its revenue from the USA. The company's sources of revenue consist of Teams, Agency, and SaaS + Advertising.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.